Skip to main content
Damian Green, MD, Oncology, Seattle, WA, UW Medicine/University of Washington Medical Center

DamianJonathanGreenMD

Oncology Seattle, WA

Hematologic Oncology

Assistant Professor, Medicine, University of Washington School of Medicine

Dr. Green is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Green's full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2004 - 2006
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 2000 - 2003
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2000

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2004 - 2024
  • OH State Medical License
    OH State Medical License 2000 - 2005
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma  
    Parameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica

Abstracts/Posters

  • High-Throughput Functional Drug Screening and Genomic Analysis to Guide Individualized Therapy for Relapsed/Refractory Multiple Myeloma
    Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...
    Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
    Damian J. Green, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Dr. Damian Green Awarded $3.2 Million to Test Radioimmunotherapy for Multiple Myeloma
    Dr. Damian Green Awarded $3.2 Million to Test Radioimmunotherapy for Multiple MyelomaMarch 17th, 2017
  • Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and More
    Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019
  • Tip Sheet: Understanding How the Flu Virus Works; Addressing Global Health Challenges in Sub-Saharan Africa; And Using Radioimmunotherapy to Destroy Multiple Myeloma Cells
    Tip Sheet: Understanding How the Flu Virus Works; Addressing Global Health Challenges in Sub-Saharan Africa; And Using Radioimmunotherapy to Destroy Multiple Myeloma CellsSeptember 5th, 2019
  • Join now to see all

Hospital Affiliations